ARCHIVES

Congressional subcommittee criticizes NIH for lax conflict of interest policies. NIH Director Zerhouni promises change. The subcommittee has asked several NCI officials to testify at another hearing next week.

This article is from The Cancer Letter archive.

Vol. 30 No. 20 | May 14, 2004

Download PDF Visit The Full Archive

Related Articles

Marijuana-Derived Drug Less Effective Than Standard

March 29, 2002

Q & A: NCI’s Doroshow Says Phase I Program Will Stress Correlative Studies for Small Biotech Firms

April 6, 2012

Bush Signs Bill To Increase Blood Cancer Research.

May 17, 2002

FDA Committee Okays Leuprolide NDA, But Recommends Against Mitoxantrne, Epirubicin

April 5, 1985

House Disallows NCI Recision

March 14, 1975

NHLBI Advisers Commit Funding TO NCI’s Women’s Health Trials, Tamoxifen Trial

March 8, 1991